Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Meiji Seika Pharma Co., Ltd.

News headline image
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma: First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis in the United States and Canada
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183, a Selective PDE4 Inhibitor for the Treatment of Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
News headline image
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis
From Meiji Seika Pharma Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.